HARBINGER MEDICAL GROUP LLC DBA TIDES MEDICAL

View full entity profile (contributions, contracts, SEC) →

Lobbying Spend

—

Filings

Firms Hired

Active Period

2021–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	—	3	1
2025	—	4	1
2024	—	4	1
2023	—	5	1
2022	—	4	1
2021	—	5	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
THE PICARD GROUP, LLC	—	25

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	24
SENATE	24
Centers For Medicare and Medicaid Services (CMS)	6
Health & Human Services, Dept of (HHS)	5
Office of Management & Budget (OMB)	2
White House Office	2

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Medicare/Medicaid	Medicare/Medicaid	25
Health Issues	Health Issues	20

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 5768119th Congress

Skin Substitute Access and Payment Reform Act

2026 · third_quarter · Firm: THE PICARD GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers; H.R.5768 Skin Substitute Access and Payment Reform Act; S.2561 Skin Substitute Access and Payment Reform Act; and H.R.6852 Advanced Wound Care and Regenerative Medicine Access

Client expense: — · Firm income: —

Matched citations: H.R.5768

H.R. 6852119th Congress

Advanced Wound Care and Regenerative Medicine Access and Reform Act

2026 · third_quarter · Firm: THE PICARD GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers; H.R.5768 Skin Substitute Access and Payment Reform Act; S.2561 Skin Substitute Access and Payment Reform Act; and H.R.6852 Advanced Wound Care and Regenerative Medicine Access

Client expense: — · Firm income: —

Matched citations: H.R.6852

S. 2561119th Congress

Skin Substitute Access and Payment Reform Act of 2025

2026 · third_quarter · Firm: THE PICARD GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers; H.R.5768 Skin Substitute Access and Payment Reform Act; S.2561 Skin Substitute Access and Payment Reform Act; and H.R.6852 Advanced Wound Care and Regenerative Medicine Access

Client expense: — · Firm income: —

Matched citations: S.2561

H.R. 5768119th Congress

Skin Substitute Access and Payment Reform Act

2026 · second_quarter · Firm: THE PICARD GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers; H.R.5768 Skin Substitute Access and Payment Reform Act; S.2561 Skin Substitute Access and Payment Reform Act; and H.R.6852 Advanced Wound Care and Regenerative Medicine Access

Client expense: — · Firm income: —

Matched citations: H.R.5768

Show 21 more cited filings

H.R. 6852119th Congress

Advanced Wound Care and Regenerative Medicine Access and Reform Act

2026 · second_quarter · Firm: THE PICARD GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers; H.R.5768 Skin Substitute Access and Payment Reform Act; S.2561 Skin Substitute Access and Payment Reform Act; and H.R.6852 Advanced Wound Care and Regenerative Medicine Access

Client expense: — · Firm income: —

Matched citations: H.R.6852

S. 2561119th Congress

Skin Substitute Access and Payment Reform Act of 2025

2026 · second_quarter · Firm: THE PICARD GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers; H.R.5768 Skin Substitute Access and Payment Reform Act; S.2561 Skin Substitute Access and Payment Reform Act; and H.R.6852 Advanced Wound Care and Regenerative Medicine Access

Client expense: — · Firm income: —

Matched citations: S.2561

H.R. 5768119th Congress

Skin Substitute Access and Payment Reform Act

2026 · first_quarter · Firm: THE PICARD GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers; H.R.5768 Skin Substitute Access and Payment Reform Act; S.2561 Skin Substitute Access and Payment Reform Act; and H.R.6852 Advanced Wound Care and Regenerative Medicine Access

Client expense: — · Firm income: $50,000

Matched citations: H.R.5768

H.R. 6852119th Congress

Advanced Wound Care and Regenerative Medicine Access and Reform Act

2026 · first_quarter · Firm: THE PICARD GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers; H.R.5768 Skin Substitute Access and Payment Reform Act; S.2561 Skin Substitute Access and Payment Reform Act; and H.R.6852 Advanced Wound Care and Regenerative Medicine Access

Client expense: — · Firm income: $50,000

Matched citations: H.R.6852

S. 2561119th Congress

Skin Substitute Access and Payment Reform Act of 2025

2026 · first_quarter · Firm: THE PICARD GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers; H.R.5768 Skin Substitute Access and Payment Reform Act; S.2561 Skin Substitute Access and Payment Reform Act; and H.R.6852 Advanced Wound Care and Regenerative Medicine Access

Client expense: — · Firm income: $50,000

Matched citations: S.2561

H.R. 5768119th Congress

Skin Substitute Access and Payment Reform Act

2025 · fourth_quarter · Firm: THE PICARD GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers; H.R.5768 Skin Substitute Access and Payment Reform Act; S.2561 Skin Substitute Access and Payment Reform Act; and H.R.6852 Advanced Wound Care and Regenerative Medicine Access

Client expense: — · Firm income: $50,000

Matched citations: H.R.5768

H.R. 6852119th Congress

Advanced Wound Care and Regenerative Medicine Access and Reform Act

2025 · fourth_quarter · Firm: THE PICARD GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers; H.R.5768 Skin Substitute Access and Payment Reform Act; S.2561 Skin Substitute Access and Payment Reform Act; and H.R.6852 Advanced Wound Care and Regenerative Medicine Access

Client expense: — · Firm income: $50,000

Matched citations: H.R.6852

S. 2561119th Congress

Skin Substitute Access and Payment Reform Act of 2025

2025 · fourth_quarter · Firm: THE PICARD GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers; H.R.5768 Skin Substitute Access and Payment Reform Act; S.2561 Skin Substitute Access and Payment Reform Act; and H.R.6852 Advanced Wound Care and Regenerative Medicine Access

Client expense: — · Firm income: $50,000

Matched citations: S.2561

H.R. 2087116th Congress

Drug Price Transparency Act

2022 · fourth_quarter · Firm: THE PICARD GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Drug price transparency act language included in HR 2087; Consolidated Appropriations Act of 2021; Medicare Advantage issue related to skin substitutes; Calendar Year (CY) 2023 proposed Medicare Physician Fee Schedule.

Client expense: — · Firm income: $50,000

Matched citations: HR 2087

H.R. 2087116th Congress

Drug Price Transparency Act

2022 · fourth_quarter · Firm: THE PICARD GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Drug price transparency act language included in HR 2087; Consolidated Appropriations Act of 2021; Medicare Advantage issue related to skin substitutes; Calendar Year (CY) 2023 proposed Medicare Physician Fee Schedule.

Client expense: — · Firm income: $50,000

Matched citations: HR 2087

H.R. 2087116th Congress

Drug Price Transparency Act

2022 · third_quarter · Firm: THE PICARD GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Drug price transparency act language included in HR 2087; Consolidated Appropriations Act of 2021; Medicare Advantage issue related to skin substitutes; Calendar Year (CY) 2023 proposed Medicare Physician Fee Schedule.

Client expense: — · Firm income: $50,000

Matched citations: HR 2087

H.R. 2087116th Congress

Drug Price Transparency Act

2022 · third_quarter · Firm: THE PICARD GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Drug price transparency act language included in HR 2087; Consolidated Appropriations Act of 2021; Medicare Advantage issue related to skin substitutes; Calendar Year (CY) 2023 proposed Medicare Physician Fee Schedule.

Client expense: — · Firm income: $50,000

Matched citations: HR 2087

H.R. 2087116th Congress

Drug Price Transparency Act

2022 · second_quarter · Firm: THE PICARD GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Drug price transparency act language included in HR 2087; Consolidated Appropriations Act of 2021; Medicare Advantage issue related to skin substitutes.

Client expense: — · Firm income: $50,000

Matched citations: HR 2087

H.R. 2087116th Congress

Drug Price Transparency Act

2022 · second_quarter · Firm: THE PICARD GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Drug price transparency act language included in HR 2087; Consolidated Appropriations Act of 2021; Medicare Advantage issue related to skin substitutes.

Client expense: — · Firm income: $50,000

Matched citations: HR 2087

H.R. 2087116th Congress

Drug Price Transparency Act

2022 · first_quarter · Firm: THE PICARD GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Drug price transparency act language included in HR 2087; Consolidated Appropriations Act of 2021; Medicare Advantage issue related to skin substitutes.

Client expense: — · Firm income: $50,000

Matched citations: HR 2087

H.R. 2087116th Congress

Drug Price Transparency Act

2022 · first_quarter · Firm: THE PICARD GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Drug price transparency act language included in HR 2087; Consolidated Appropriations Act of 2021; Medicare Advantage issue related to skin substitutes.

Client expense: — · Firm income: $50,000

Matched citations: HR 2087

H.R. 2087116th Congress

Drug Price Transparency Act

2021 · fourth_quarter · Firm: THE PICARD GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Drug price transparency act language included in HR 2087; Consolidated Appropriations Act of 2021; additional COVID relief legislation

Client expense: — · Firm income: $50,000

Matched citations: HR 2087

H.R. 2087116th Congress

Drug Price Transparency Act

2021 · fourth_quarter · Firm: THE PICARD GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Drug price transparency act language included in HR 2087; Consolidated Appropriations Act of 2021; additional COVID relief legislations

Client expense: — · Firm income: $50,000

Matched citations: HR 2087

H.R. 2087116th Congress

Drug Price Transparency Act

2021 · third_quarter · Firm: THE PICARD GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Drug price transparency act language included in HR 2087; Consolidated Appropriations Act of 2021; additional COVID relief legislations

Client expense: — · Firm income: $50,000

Matched citations: HR 2087

H.R. 2087116th Congress

Drug Price Transparency Act

2021 · third_quarter · Firm: THE PICARD GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Drug price transparency act language included in HR 2087; Consolidated Appropriations Act of 2021; additional COVID relief legislation

Client expense: — · Firm income: $50,000

Matched citations: HR 2087

H.R. 2087116th Congress

Drug Price Transparency Act

2021 · second_quarter · Firm: THE PICARD GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Drug price transparency act language included in HR 2087; Consolidated Appropriations Act of 2021; additional COVID relief legislations

Client expense: — · Firm income: $50,000

Matched citations: HR 2087

Source: Senate LDA

HARBINGER MEDICAL GROUP LLC DBA TIDES MEDICAL — Lobbying Disclosure | Poliscope